WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 680

Summary of HB 680 (2026RS) — Kentucky

Purpose and intent

HB 680 is an act addressing controlled substances in Kentucky. It creates new provisions related to possession penalties in hospital settings, expands the state’s drug monitoring and reporting framework, strengthens licensing board oversight of controlled-substance prescribing and dispensing, and updates penalties and treatment options for unlawful possession offenses. The overarching aim is to deter unlawful possession, improve overdose response, and enhance monitoring of controlled substances across medical and cannabis contexts.

Key provisions and changes

  • Hospital-based unlawful possession (new section in KRS Chapter 218A)

    • Possession of Schedule I or II controlled substances within a hospital building, on hospital grounds, or on hospital premises owned/controlled by a hospital is a Class D felony, unless a higher penalty applies elsewhere in statute.
    • Hospitals must display a prominent sign warning that unlawful possession on hospital property is a felony punishable by up to 5 years’ imprisonment and a $10,000 fine. Failure to post the sign is not a defense.

  • Overdose-related protections and good faith use (KRS 218A.133)

    • People who in good faith seek medical assistance for a drug overdose and remain with the person experiencing the overdose are not to be charged with certain drug offenses if the overdose-related evidence is obtained as a result of the overdose encounter.
    • Requires health departments to contact the overdose caller (if information is available) to offer treatment referrals.
    • Law enforcement overdifferential liability protections for good-faith overdose assistance arrests.

  • Unlawful possession in first-degree (KRS 218A.1415)

    • Redefined to include possession of: Schedule I or II narcotics, a controlled-substance analogue, methamphetamine, LSD, PCP, GHB and its analogues, and flunitrazepam.
    • Penalty generally a Class D felony; includes options for deferred/probation-based dispositions for first/second offenses; presumptive probation available if not in deferred program.

  • Unlawful possession in second and third degrees; and hospital provisions (KRS 218A.1416, 218A.1417)

    • Second degree: Class A misdemeanor, with specific lists of substances including certain Schedule III drugs (and analogues).
    • Third degree: Class A misdemeanor for possession of Schedule IV/V substances.

  • Electronic monitoring system for controlled substances and medicinal cannabis (KRS 218A.202; related sections)

    • Establishes an electronic monitoring system to track Schedule II–V substances and medicinal cannabis.
    • Requires practitioners and pharmacies to register and report dispensing data; hospitals and emergency departments have reporting requirements for overdose-related toxicology data.
    • Data access is tightly restricted to defined officials and entities (boards, law enforcement, Medicaid, grand juries, certain medical and legal authorities) and includes privacy protections; improper disclosure carries penalties.
    • Mandates reporting timelines (data within one day of dispensing, with other provisions for data handling, archiving, and error corrections).
    • Extends to medicinal cannabis: registration for practitioners and cannabis businesses; system must support certification issuance tracking, card verification, and real-time data sharing among licensed dispensaries, law enforcement, and relevant boards.

  • Licensing boards and prescriber standards (KRS 218A.205)

    • Boards must establish mandatory prescribing/dispensing standards, aligned with CDC opioid guidelines, including limits on Schedule II pain prescriptions in acute scenarios (with several exceptions).
    • Provisions for temporary license suspensions, expedited complaint investigations, and a permanent bar on certain felonies related to controlled substances.
    • Requires fingerprint-based background checks for initial licensure and authorizes ongoing data reporting to the National Practitioner Data Bank.
    • Adds continuing education requirements focused on the monitoring system, pain management, and addiction disorders (minimum 7.5% of CE).

  • Treatment and court-ordered rehabilitation (KRS 218A.275)

    • Courts may order treatment or recovery programs for first-time offenders, with a one-year treatment period and discharge procedures, along with potential voiding of the conviction upon successful completion.

  • Paraphernalia definitions and exceptions (KRS 218A.500)

    • Updates and clarifies definitions of drug paraphernalia; preserves certain exemptions for medicinal cannabis accessories and needle exchange programs where allowed, and outlines penalties for violations.

Who would be affected

  • Individuals charged with unlawful possession of controlled substances, including those on hospital property.
  • Public safety personnel and hospitals, which must implement signage and data-sharing obligations.
  • Practitioners, pharmacists, and medicinal cannabis professionals who would register with and report to the new monitoring system.
  • State licensing boards (medical, nursing, dentistry, optometry, podiatry, etc.) that regulate controlled-substance prescribers and licensees.
  • Courts and treatment providers involved in diversion and court-ordered treatment programs.
  • The Medicaid program and, indirectly, Medicaid recipients and providers through data-sharing provisions.

Procedural and timeline highlights

  • Establishment of an electronic monitoring system with data-sharing protocols and error tolerances.
  • Data reporting deadlines: at least daily reporting for dispensed Schedule II–V substances; overdose-related data collection by hospitals; periodic quarterly reviews by the Office of the Inspector General.
  • Transition and training requirements for boards, law enforcement, and medical professionals on use of the new system.
  • Several sections provide transition timelines (e.g., system capabilities targeted by July 1, 2024 for medicinal cannabis components).

Note: This summary reflects the bill text as introduced/unofficial copy; final enacted language may differ.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.